Contact

Customer Testimonials

Our aim is to meet or exceed our customers’ expectations. Have a look at the testimonials below and let us convince you of the high quality of our products and services.

PepTrack™ Peptide Libraries

 “My group at the Virology Department of the UK Animal Health and Veterinary Laboratories Agency focuses on defining the T cell target antigens of important veterinary viral pathogens and the exploitation of this information in the development of new/improved vaccines. Our need for economic whole viral proteome spanning peptide libraries led us to JPT's PepTrack™ Peptide Libraries. The sensitivity of our cellular assays towards cytotoxic contaminants as well as impurities yielding in unwanted T-cell stimulation prompted a systematic evaluation of peptide sources. JPT turned out to be the most reliable vendor regarding both delivery time and high quality levels based on a certified Quality Management System. I am collaborating with JPT for many years and certainly recommend their services.”
Simon Graham, PhD (Virology Department of the UK Animal Health and Veterinary Laboratories Agency, Addlestone, Surrey, UK

"I have been collaborating with JPT for several years. Their unique peptide library technologies and knowledge of specific peptide requirements for T-cell assays made them a valuable, long-term partner in our efforts to develop novel adoptive immunotherapy approaches to prevent and treat viral infections post-transplant as well as for the treatment of virus and non virus-associated malignancies. Furthermore, their reagents allow us to precisely monitor and track specific T cell populations post-infusion"
Ann Leen, PhD (Baylor College of Medicine, Center for Cell and Gene Therapy, Houston, TX, USA)

PepMix™ Peptide Pools

"To establish a novel role for myeloid derived suppressor cells (Pallett et al, Nat. Med. 2015) in chronic viral infection, we utilised the PepMix CEF Pool (extended) as well as a custom synthesized PepMix spanning the core region of HBV genotype D .  Whereas, the CEF peptide pool consists of 32 peptides, each corresponding to a defined HLA class I-restricted T-cell epitope from Cytomegalo, Epstein-Barr, and Influenza virus, the latter custom PepMix included 15meric peptides overlapping by 10 amino acids.  Specifically this composition enabled us to monitor both the antiviral CD8+ and CD4+ T cell responses in chronic HBV infection and the non-antigen specific T cells that are known to mediate immunopathology in the liver. Our entire experience with JPT, from ordering/delivery to use in the lab was excellent. Not only were the reagents able to perform reliably and consistently in vitro from batch to batch, the customer and technical support provided was continually available and efficient when needed. JPT will remain our "go-to" company for purchasing peptides."
Dr Laura J Pallett, Infection and Immunity, University College London, UK.

"The main focus of my research group at the Charité in Berlin is the development of novel immunotherapeutic approaches against cancer and infectious diseases. For reliable monitoring of tumor and virus specific T-cell responses we have a permanent need for peptides and peptide pools that are produced in a regulated environment for application in a clinical environment. JPT has been a long term and dedicated partner in this regard which continuously works on improving it's peptide based services."
Prof. Dr. Carmen Scheibenbogen (Charité Berlin, Berlin, Germany)

Clinical Peptides & Pools

"My group is developing therapeutic strategies for using in vitro expanded virus-specific T cells (VSTs) for the treatment of viral infections in immunocompromised patients. We recently demonstrated the feasibility and clinical benefit associated with the infusion of rapidly generated single-culture VSTs, manufactured using JPT's GxP PepMix™ peptide pools covering 12 immunogenic antigens from five viruses (EBV, AdV, CMV, BK, and HHV6). When administered to 11 allogeneic stem cell transplant recipients, 8 of whom had up to four active infections, these VSTs produced an overall 94% response rate."
Ann Leen, PhD, Baylor College of Medicine, Houston, TX, USA 

"We utilize customized 15-mer PepMix™ peptide pools encoding for weak tumor associated antigens for immunomonitoring of cancer patients treated with recombinant therapeutic vaccines.  Our experience with JPT has been outstanding in regard to product quality and communication with scientific and administrative customer service.  JPT is the only company we trust to synthesize the 15-mer peptides and corresponding pools for our clinical trial evaluations." 
Benedetto Farsaci, MD, National Cancer Institute, NIH, Bethesda, MD, USA 

"Our work focuses on TGF-beta in physiology and cancer as well as the differentiation and expansion of human T cells in vitro for  adoptive immunotherapy. For our early phase clinical trials we are in need of T cell EBV specific stimulants having an exceptional quality. JPT's customized  PepMix™Peptide Pools not only proved to deliver excellent performance in our in vitro culture systems but accompanying QC/QA documentation was essential to prepare our application to our regulatory agency.”
Dr. Jean-Sébastien Delisle, Université de Montréal, Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Canada

PepStar™ Peptide Microarrays

"Over the past five years my research team has been active in the development of species-specific peptide arrays. Our ability to advance this technology into new research areas has been dependent on working with the highest quality of arrays. In this regard, JPT’s commitment to excellence has been a critical foundation for the success of our research program.  I have been consistently impressed with their customer service, technical expertise and professionalism. When it comes to peptide work there are no other options for our group…JPT is the best."
Scott Napper, PhD (Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Canada)

"We study modulation of dopaminergic neurotransmisson by TAAR1 and D2R. The functional interaction of the two receptors in the brain supports TAAR1 as a target for the treatment of psychiatric disorders such as schizophrenia or bipolar disorder. To map the epitopes of our newly generated specific anti-rat TAAR1 antibodies we used JPT's PepStarTM peptide microarrays. The peptide microarrays greatly contributed to our successful and recently published study. We were very satisified with the exceptional product and service delivered by JPT Peptide Technologies as well as their scientific Customer Support which was always at our disposal."
Stefan Obermüller, F.Hoffmann – La Roche Ltd., Roche Pharma Research and Early Development, Basel, Switzerland

PepSpots™ Peptides on Cellulose

“Our teams at the Vrije Universiteit Brussel deal with a wide variety of projects in different areas of applied biological sciences. For many of them we are in need of peptide related tools and services ranging from peptide libraries and highly purified peptides to peptide arrays. In our search for an integrated and reliable provider we came across JPT. Meanwhile, we are collaborating with JPT for many years and are very satisfied with the relationship which led to several well received publications. Especially, their unique array technology PepSpots™ helped us to enhance our knowledge on different protein protein interactions such as Chaperone-substrate recognition.”  
Prof. Dr. Joost Schymkowitz (Vrije Universiteit, Brussel, Belgium)

Peptide Modifications & Specialty Peptides

"The RV 144 HIV trial is considered as one of first successful HIV vaccine trials. It has become clear that the V2 loop of gp120 is an important site for immunogenicity and protection from HIV infection. The use of JPT's PepStarTM microarray technology has been very useful for the correlation of the clincial outcome with humoral immune responses. As have the cyclic peptides been from JPT to validate these findings!"
J. Currier, PhD, Walter Reed Army Institute, Rockville, Maryland, USA

"Our research relies heavily on developing robust high-throughput screens with fluorescent peptides.  We have found that JPT’s are the best on the market because the signal-to-noise ratio is very high, providing the sensitivity we need for the screens. Their peptides always perform well. In addition, the knowledge, wonderful customer support, and fast turnaround time provided by JPT have been invaluable in helping us develop the best peptides for our assays."
Prof. Carla Koehler (UCLA, Los angeles, CA, USA)

Amyloid beta peptides (or Aβ, Abeta, Beta Amyloid)

“Our group focuses on the in vitro study of risk factors in Alzheimer’s disease and, as we experienced that the in-house expression and production of the amyloid beta peptide is notoriously difficult, we are continuously dependent on a high quality supply of a large variety of these peptides from commercial source.  We started our collaboration with JPT with their request to test a range of their peptides for the ability to produce toxic oligomers and fibrillar networks and were impressed by the rapid supply of a very wide range of high purity peptides with excellent fibril forming properties and toxicity profiles. JPT has shown real valuable know-how and experience in the field of peptide synthesis by their ability to generate high quality preparations of amyloid beta peptide variants which are known for their difficulty to handle.”
Kerensa Broersen, Assistant Prof., Nanobiophysics Group, University of Twente, Enschede, The Netherlands

Micro-Scale Peptide Sets

"Our group at OHSU has purchased more than 50 000 peptides over the past few years from JPT to support our proteome wide TB epitope discovery program.  We are impressed by the turnaround times and highly competitive pricing structure for such large numbers of peptides and are very satisfied with the responsive and professional service."
Gwendolyn Swarbrick (Oregon Health & Science University, USA)

“Our teams at the Vrije Universiteit Brussel deal with a wide variety of projects in different areas of applied biological sciences. For many of them we are in need of peptide related tools and services ranging from peptide libraries and highly purified peptides to peptide arrays. In our search for an integrated and reliable provider we came across JPT. Meanwhile, we are collaborating with JPT for many years and are very satisfied with the relationship which led to several well received publications. Especially, their unique array technology PepSpots™ helped us to enhance our knowledge on different protein protein interactions such as Chaperone-substrate recognition.”  
Prof. Dr. Joost Schymkowitz (Vrije Universiteit, Brussel, Belgium)

Enzyme Profiling Tools

"With JPT´s peptide microarray platform, high- throughput kinase profiling using small amounts of cell lysate becomes feasible, providing access to the discovery and monitoring of novel biomarkers in Parkinson's Disease. "
Jeremy Nichols, PhD (Parkinsons's Institute, Sunnyvale, CA, USA)

"JPT’s new extremely high-density histone peptide array is a dramatic leap forward for analysis of the histone code hypothesis. The complete sequence coverage across core histones and histone variants as well as the presence of common and rare histone post-translational modifications – alone and in combination – makes this an unparalleled tool for studying the “writers” and “readers” of the histone code. My laboratory has used these arrays to ask the sequence and PTM dependence of a histone writer enzyme and we have discovered an activity specifying code that will keep us busy for years to come."
David Shechter, PhD, Department of Biochemistry, Albert Einstein College of Medicine,  Yeshiva University, NY, USA

Reference Peptides for Targeted Proteomics - SpikeTides™ & SpikeMix™

"At Cambridge University we have significantly benefited from a suite of SpikeTides™ from JPT which have been developed for use as organelle markers in Arabidopsis. Using these we have developed faster and more accurate methods, using SRM and PRM, for estimating organelle enrichment along linear density gradients. Results have been very instrumental in optimizing downstream methodologies, a process which has delivered improved resolution in ensuing datasets for lower costs than our original methods."
Harriet Parsons, PhD (Department of Biochemistry, University of Cambridge, UK)

"At MSKCC, we have been using JPT for isotopically labeled peptide libraries for developing pathway- and genome-scale atlases for quantitation of cellular signaling. This has been invaluable for the Quantitative Cell Proteomics Atlas (QCPA), a research tool for precise and sensitivity quantitation of cellular signaling, as well as clinical diagnostic assays for medical use."

Alex Kentsis, MD, PhD (Memorial Sloan Kettering Institue, New York, USA)

Absolute Quantified Peptides - SpikeTides™ TQL & SpikeTides™ TQL PLUS

"My group studies the proteomic composition of distinct chromatin domains, the mechanisms that operate to maintain the composition of histone modifications and the associated proteins. For precise and accurate identification and quantification of histone peptides that carry multiple post-translational modifications directly from biological samples JPT's SpikeTides™_TQL peptide standards proved to be of excellent value for our research in various projects."
Prof. Dr. Axel Imhof, Adolf-Butenandt Institute, University of Munich, Germany

"My unit at the Banting and Best Department of Medical Research, University of Toronto Centre for Cellular and Biomolecular Research (CCBR) works on the systematic identification and quantification of proteins and protein complexes on a global level. In addition we have started to perform targeted proteomics to study protein regulation within pathways, e.g. signaling pathways during stem cell fate decision. For this we used JPT's various SpikeTides™ peptide products to build LC-MRM assays in a fast and cost efficient manner. More recently we also found new ways of using low cost SpikeTides™ as quantitative peptide standards in order to quantify protein targets more accurately. We are currently in the process of validating this technology for the accurate quantification of various predicted microRNA targets."
Prof. Andrew Emili (Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Canada)

Proteomics Peptide Standards - SpikeMix™ & SpikeTides™ Kits

"As Director of the Protein Profiling at Yale Keck Biotechnology Resource Facility, I coordinated a collaboration between the Association of Biomolecular Resource Facilities (ABRF) standard proteomic research group (sPRG) and JPT Peptide Technologies to develop the ABRF cross-species SpikeMix™ Peptide Pool. The joint development turned out to be an extraordinary effective endeavor and the resulting product was qualified in more than 52 proteomics labs around the globe. I was impressed by JPT's scientific and technological capabilities as well as their enthusiasm to drive the project forward."
Christopher M. Colangelo, Director of Protein Profiling at Keck Biotechnology Resource Facility, Yale University, USA

"Our research at Stanford University seeks to discover unconventional translation products, and proteins made by unsequenced organisms; to characterize a wide array of protein post-translational modifications; and to perform peptide antigen binding assays.  On all of these fronts, we are in need of high quality peptide standards for assay development and protein quantification. The successful collaboration with the team at JPT Peptide Technologies and their wide range of products has been a critical factor for advancing my group’s research."
Joshua E. Elias, Ph.D., Chemical & Systems Biology, Stanford University School of Medicine, Clark Center, Stanford, CA 

BioTides™ Biotinylated Peptides

"Our group at OHSU has purchased more than 50 000 peptides over the past few years from JPT to support our proteome wide TB epitope discovery program.  We are impressed by the turnaround times and highly competitive pricing structure for such large numbers of peptides and are very satisfied with the responsive and professional service."
Gwendolyn Swarbrick (Oregon Health & Science University, USA)

Protein Interaction Screen on Peptide Matrix (PRISMA)

"My research groups at the Max Delbrück Center for molecular medicine (MDC) and the Luxembourg institute of health (LIH) work on the systematic characterization of protein-protein interactions and the regulation of these interactions by post-translational modifications. Therefore we developed PrISMa (Protein Interaction Screen on a peptide Matrix) a method for the systematic analysis of these interactions and their regulation which helped us to uncover a complex, interwoven interaction network. JPT’s peptide membranes in combination with high-resolution mass spectrometry made the development of PrISMa possible. "
Gunnar Dittmar, PhD, Proteome and Genome research laboratory, Luxembourg Institute of Health, Strassen, Luxembourg

Stay in touch and be the first to receive the latest news!